Ghost Tree Capital’s Altimmune ALT Stock Holding History

Ghost Tree Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400,000	Closed	-$1.69M	–	59
2023 Q1	$1.69M	Buy	+400,000	New	+$4.75M	0.5%	43

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ghost Tree Capital's ALT Position: Q2 2024 in Review

Ghost Tree Capital sold out of Altimmune (ALT) in Q2 2024, closing a stake of 250,000 shares — an estimated $2.54M sold.

Ghost Tree Capital first reported a position in ALT in Q2 2020 and held it in 4 quarters. The position peaked at $5.55M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q2 2024.

Ghost Tree Capital reported no remaining Altimmune position as of Q2 2024 after selling out during the quarter.
Ghost Tree Capital sold 250,000 Altimmune shares in Q2 2024, an estimated $2.54M.
Ghost Tree Capital first reported a position in Altimmune in Q2 2020 and held it in 4 quarters.
Ghost Tree Capital's Altimmune position peaked at $5.55M in Q3 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.